Literature DB >> 9590216

In situ immune response in gut-associated lymphoid tissue (GALT) following oral antigen in TCR-transgenic mice.

P A Gonnella1, Y Chen, J Inobe, Y Komagata, M Quartulli, H L Weiner.   

Abstract

Oral administration of Ag results in systemic hyporesponsiveness termed oral tolerance. The regulatory cells induced by oral Ag are effective in the suppression of Th1-type autoimmune diseases. We examined the cytokine microenvironment in gut-associated lymphoid tissue in response to orally administered OVA in OVA TCR-transgenic mice. Mice were fed a low (0.5 mg) or high (500 mg) dose of OVA one time or five times. Immunohistochemical analysis demonstrated increased IL-4, IL-10, and TGF-beta in the gut within 6 h of a low-dose feeding and after five low-dose or high-dose feedings. IFN-gamma and IL-2 either decreased or showed no change, with the exception of a small transient increase in IL-2 at 6 h after a low dose. Increases in IL-4 and IL-10 were found in the dome of the Peyer's patch, and increases in TGF-beta were observed in the interfollicular region and the villi. IL-10 was also substantially increased in the villi. IL-4 and IL-10 were produced predominately by CD4+ T cells. TGF-beta was found predominately in macrophages and CD4+ T cells. Peyer's patches had a marked up-regulation of TGF-beta mRNA as measured by RT-PCR. These results demonstrate the differential activation of cytokine production in discrete regions of gut-associated lymphoid tissue. The induction of cytokines known to inhibit autoimmune disease at the site of Ag absorption indicates an important role for the mucosal immune system in the establishment of oral tolerance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9590216

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

Review 1.  Control of immune pathology by IL-10-secreting regulatory T cells.

Authors:  S Fowler; F Powrie
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.

Authors:  H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

3.  Active suppression in orally tolerized rats coincides with in situ transforming growth factor-beta (TGF-beta) expression in the draining lymph nodes.

Authors:  B S Lundin; M R Karlsson; L A Svensson; L A Hanson; U I Dahlgren; E Telemo
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

4.  TGF-beta/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation.

Authors:  C Fiocchi
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

5.  The effects of epiphyseal peptides on the release of immunoglobulins in Peyer's patches in rats in vitro.

Authors:  O A Zimina; R I Kovalenko; A D Nozdrachev
Journal:  Neurosci Behav Physiol       Date:  2003-11

Review 6.  Innate signaling networks in mucosal IgA class switching.

Authors:  Alejo Chorny; Irene Puga; Andrea Cerutti
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

7.  Effect of specific antigen stimulation on intraepithelial lymphocyte migration to small intestinal mucosa.

Authors:  S Komoto; S Miura; S Koseki; M Goto; S Hachimura; H Fujimori; R Hokari; Y Hara; T Ogino; C Watanabe; H Nagata; S Kaminogawa; T Hibi; H Ishii
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

Review 8.  Oral tolerance and the treatment of rheumatoid arthritis.

Authors:  H L Weiner; Y Komagata
Journal:  Springer Semin Immunopathol       Date:  1998

9.  Role of CTLA-4, IL-18 and IL-10 on the Induction of Low Dose Oral Tolerance.

Authors:  Kathleen Siobhan Barone; Rachael Burns; Stephanie Horton; Armando Retana; Lindsey Jackson Meredith Wall; Tifany Nolan
Journal:  J Ky Acad Sci       Date:  2008-03-01

10.  Oral tolerization with cardiac myosin peptide (614-629) ameliorates experimental autoimmune myocarditis: role of STAT 6 genes in BALB/CJ mice.

Authors:  Patricia A Gonnella; Pedro J Del Nido; Francis X McGowan
Journal:  J Clin Immunol       Date:  2009-04-08       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.